Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Urology · Prostate Cancer

What Do PI-RADS 3, 4, and 5 Mean on a Prostate MRI?

At a Glance

PI-RADS 3 means a prostate MRI finding is uncertain, while PI-RADS 4 and 5 indicate increasing suspicion for clinically significant prostate cancer. The score is not a diagnosis; PSA level relative to prostate size, prior biopsy results, and other factors guide biopsy or monitoring.

In this answer

4 sections

01

What the Scores Mean (and What They Don’t)

02

Evaluating a PI-RADS 3 Result

03

Discussing a Biopsy for PI-RADS 4 and 5

04

What if the Biopsy Finds No Cancer?

If you have received the results of a prostate MRI, seeing a PI-RADS score of 3, 4, or 5 can be stressful. The most important thing to understand is that a PI-RADS score measures the probability or suspicion that clinically significant prostate cancer is present [1][2]. It is not a cancer diagnosis, nor does it tell you the stage or grade of a tumor [3].

Whether this is your first prostate MRI or you have already been diagnosed with prostate adenocarcinoma, the score helps your care team decide the next steps. For men without a diagnosis, the score helps determine whether a biopsy is appropriate [1]. For men already diagnosed with low-risk cancer who are on active surveillance, the score helps monitor for changes or assess whether the cancer might be a higher grade than initially thought [4].

What the Scores Mean (and What They Don’t)

PI-RADS (Prostate Imaging Reporting and Data System) is a standardized scale radiologists use to interpret prostate MRIs [2]. The score estimates the likelihood of finding clinically significant prostate cancer [1]. In the medical literature, “clinically significant” usually refers to cancers of a certain grade (often Grade Group 2 or higher) or size that have the potential to grow and spread [5]. It does not automatically mean you need immediate treatment, as even some clinically significant cancers are managed with active surveillance depending on the patient’s overall health and preferences [4].

The interpretation of the scan also heavily depends on the quality of the MRI images and the experience of the radiologist reading them [6][7].

  • PI-RADS 3 (Equivocal): The MRI shows an indeterminate area [1]. It is unclear if clinically significant cancer is present [1]. Research analyzing thousands of patients estimates that, on average, clinically significant cancer is found in roughly 16% to 20% of PI-RADS 3 lesions when biopsied [1][8].
  • PI-RADS 4 (High Suspicion): Clinically significant cancer is likely to be present [1]. Studies show detection rates typically around 50% to 60% [1][8].
  • PI-RADS 5 (Very High Suspicion): Clinically significant cancer is highly likely [1]. Studies show detection rates typically around 80% to 90% [1][8].

It is vital to understand that these percentages are population averages, not your personal risk [5]. Your actual risk depends on other clinical factors [5].

Evaluating a PI-RADS 3 Result

Because a PI-RADS 3 result is genuinely ambiguous, doctors rarely use the MRI alone to make decisions [9]. Instead, they look at your complete clinical picture [9].

A key metric your doctor will calculate is your PSA density [10]. This is your Prostate-Specific Antigen (PSA) blood level divided by the physical size (volume) of your prostate gland [10].

  • A lower PSA density reduces your risk of clinically significant cancer [11]. However, there is no universal cutoff that guarantees you are cancer-free; thresholds like 0.10 or 0.15 ng/mL/cc are trade-offs between finding cancer and avoiding unnecessary biopsies [12].
  • A higher PSA density, older age, a family history of prostate cancer, or an abnormal digital rectal exam (DRE) increase the risk [13][9].
  • If you have had a prior negative biopsy, your risk is generally lower [13][12].

If you do not have a cancer diagnosis and you and your doctor decide to defer a biopsy, you will typically begin a structured monitoring plan (such as PSA checks every 6 months and a repeat MRI in a year) to watch for changes [14]. (Note: This pre-diagnosis monitoring is different from “active surveillance,” which is a strategy used after cancer has been confirmed [4].)

Discussing a Biopsy for PI-RADS 4 and 5

Because scores of 4 and 5 carry a substantial risk of clinically significant cancer, they commonly prompt a recommendation to perform a prostate biopsy [15][16]. However, this is not an absolute rule [17]. The decision should account for your age, competing health issues, life expectancy, and personal preferences [17].

If you proceed with a biopsy, the MRI provides a map for the procedure:

  • Targeted Biopsy: The doctor uses the MRI images (often fused with real-time ultrasound) to guide the needles directly into the suspicious lesion [16].
  • Systematic Biopsy: Samples are taken in a standard pattern from across the entire prostate to catch anything the MRI could not see [18].

In men who have never had a biopsy, combining both methods often provides the best detection rate [19]. For example, one large study found that using only a targeted biopsy missed roughly 16% of clinically significant tumors that were caught by adding the systematic cores [18]. However, the benefit of extra systematic cores may be smaller for some PI-RADS 5 lesions or for men who have already had previous biopsies, and more cores can sometimes detect very low-risk cancers that would not have caused harm [20][21]. Your doctor will tailor the approach to your situation [21].

What if the Biopsy Finds No Cancer?

MRIs are excellent tools, but they are not perfect. Sometimes, a high-suspicion MRI is followed by a biopsy that finds no cancer. When this happens, doctors must distinguish between two possibilities:

  1. A True False Positive: The MRI saw something real, but it was not cancer [22]. Common non-cancerous conditions that mimic tumors on an MRI include inflammation (prostatitis), benign prostatic hyperplasia (BPH) nodules, normal anatomical variations, or bleeding from a previous biopsy [22].
  2. Sampling Error: Clinically significant cancer is present, but the biopsy needles simply missed the lesion [18]. Furthermore, MRIs occasionally miss small or diffusely spread tumors entirely, which can lead to a false sense of security [23][6].

Because of this uncertainty, a negative biopsy of a PI-RADS 4 or 5 lesion does not automatically close the case [24]. Your care team will likely perform a radiology-pathology concordance review—comparing the biopsy results directly against the MRI images to see if they make sense together [24]. Depending on this review, they may recommend continued monitoring, a repeat MRI, or a repeat biopsy [24][25].

Common questions in this guide

Is a PI-RADS score the same as a prostate cancer diagnosis?
No. PI-RADS estimates how suspicious a prostate MRI finding is for clinically significant prostate cancer; it does not confirm cancer or show the cancer’s stage or grade. Doctors combine the score with your PSA density, examination, history, and sometimes a biopsy.
What are the usual cancer detection rates for PI-RADS 3, 4, and 5?
Among people who undergo biopsy, studies report clinically significant cancer in about 16% to 20% of PI-RADS 3 lesions, 50% to 60% of PI-RADS 4 lesions, and 80% to 90% of PI-RADS 5 lesions. These are population averages, not a personal prediction.
What does a PI-RADS 3 result usually mean for next steps?
PI-RADS 3 is an uncertain or indeterminate finding, so doctors consider the whole clinical picture rather than the MRI alone. PSA density, age, family history, the rectal examination, and any previous biopsy can influence whether to biopsy or monitor. If biopsy is deferred, monitoring may include PSA checks about every six months and a repeat MRI in about a year.
Does PI-RADS 4 or 5 always mean I need a biopsy?
No, but these scores commonly lead to a biopsy discussion because the chance of clinically significant cancer is higher. The decision also considers your age, other health conditions, life expectancy, and preferences. If a biopsy is done, it may use MRI-targeted samples, systematic samples, or both.
Why might a biopsy be negative after a PI-RADS 4 or 5 MRI?
The MRI finding may be a noncancerous condition such as inflammation or benign prostate tissue, or the biopsy needle may have missed the lesion. Your care team may compare the MRI with the biopsy results and then recommend monitoring, another MRI, or a repeat biopsy. A negative biopsy does not always settle the question when the MRI was highly suspicious.
What is PSA density and why is it used with PI-RADS?
PSA density is the PSA blood level divided by the volume of the prostate. A lower value generally lowers the likelihood of clinically significant cancer, while a higher value raises concern, but no single cutoff rules cancer in or out. Doctors use PSA density alongside the MRI score and other clinical information.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Related questions

What to Do After a Negative Prostate Biopsy With High PSA? How Long Is ADT With Radiation for Prostate Cancer? What Is the Next Step After a High PSA? Testing Path When Is PSMA PET/CT Needed for Prostate Cancer Staging? How Are the Six Prostate Cancer Risk Groups Defined?
Show more
Can Prostatitis, BPH, Sex, or Cycling Raise PSA Levels? Can You Have Prostate Cancer With a Negative MRI, High PSA? How Do Cribriform and IDC-P Affect Prostate Cancer Risk? Surgery or Radiation Better for High-Risk Prostate Cancer? How Often Is Low-Risk Prostate Cancer Actively Monitored? Can a Second Review Change Your Prostate Cancer Grade? What Do T, N, and M Stages Mean in Prostate Cancer? Should I Get Genetic Testing After Prostate Cancer? How Do Age and Health Affect Prostate Cancer Treatment? When to Leave Active Surveillance for Prostate Cancer? Are Genomic Tests Useful for Prostate Cancer Decisions? Can Testosterone or Supplements Worsen Prostate Cancer? Why Are Prostate Biopsies Done? Risks and Methods Explained When Should I Start Prostate Cancer Screening If High Risk?

Get notified when new evidence is published on prostate adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific PI-RADS category, location, and size of the suspicious lesion on my MRI?
  2. 2.What is my calculated PSA density, and how does that change the interpretation of my MRI score?
  3. 3.Was my MRI image quality sufficient (e.g., PI-QUAL score) and was it read by a specialist in prostate imaging?
  4. 4.If a biopsy is appropriate, will you perform an MRI-targeted biopsy, a systematic biopsy, or both?
  5. 5.If my biopsy comes back negative but I had a PI-RADS 4 or 5 score, how will we review the results to ensure the needle didn't just miss the lesion?

References

References (25)
  1. 1

    Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level.

    Oerther B, Engel H, Bamberg F, et al.

    Prostate cancer and prostatic diseases 2022; (25(2)):256-263 doi:10.1038/s41391-021-00417-1.

    PMID: 34230616
  2. 2

    PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.

    Weinreb JC, Barentsz JO, Choyke PL, et al.

    European urology 2016; (69(1)):16-40.

    PMID: 26427566
  3. 3

    Diagnostic Accuracy of Combination of Multiparametric MRI PI-RADS Score v2.1 and Prostate-Specific Antigen Density for Prostate Cancer Detection.

    Shetty A, Gadupati J, Bommineni B, et al.

    Cureus 2025; (17(3)):e80238 doi:10.7759/cureus.80238.

    PMID: 40196070
  4. 4

    The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?

    Roscigno M, Stabile A, Lughezzani G, et al.

    Clinical genitourinary cancer 2020; (18(6)):e698-e704 doi:10.1016/j.clgc.2020.04.006.

    PMID: 32493676
  5. 5

    Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

    Padhani AR, Weinreb J, Rosenkrantz AB, et al.

    European urology 2019; (75(3)):385-396 doi:10.1016/j.eururo.2018.05.035.

    PMID: 29908876
  6. 6

    MRI Quality and Reader Experience in Organized Prostate Cancer Screening: Insights from the PROBASE Trial.

    Boschheidgen M, Al-Monajjed R, Schlemmer HP, et al.

    European urology oncology 2026; doi:10.1016/j.euo.2026.05.003.

    PMID: 42225542
  7. 7

    Variation in Prostate Magnetic Resonance Imaging Performance: Data from the Prostate Biopsy Collaborative Group.

    Nalavenkata SB, Vertosick E, Briganti A, et al.

    European urology oncology 2026; (9(1)):156-163 doi:10.1016/j.euo.2025.02.007.

    PMID: 40318951
  8. 8

    Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection.

    Walker SM, Mehralivand S, Harmon SA, et al.

    AJR. American journal of roentgenology 2020; (215(5)):1098-1103 doi:10.2214/AJR.19.22679.

    PMID: 32877244
  9. 9

    When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy.

    Lim CS, Abreu-Gomez J, Leblond MA, et al.

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2021; (15(4)):115-121 doi:10.5489/cuaj.6781.

    PMID: 33007183
  10. 10

    Creating a novel multiparametric magnetic resonance imaging-based biopsy strategy for reducing unnecessary prostate biopsies: a retrospective cohort study.

    Wang C, Shen D, Yuan L, et al.

    Quantitative imaging in medicine and surgery 2024; (14(2)):2021-2033 doi:10.21037/qims-23-875.

    PMID: 38415121
  11. 11

    Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.

    Haj-Mirzaian A, Burk KS, Lacson R, et al.

    JAMA network open 2024; (7(3)):e244258 doi:10.1001/jamanetworkopen.2024.4258.

    PMID: 38551559
  12. 12

    Prediction of Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging Lesions: A High-volume International Multicenter Study.

    Sigle A, Borkowetz A, von Hardenberg J, et al.

    European urology focus 2023; (9(4)):606-613 doi:10.1016/j.euf.2023.01.020.

    PMID: 36804191
  13. 13

    Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.

    Fang AM, Shumaker LA, Martin KD, et al.

    Cancer 2022; (128(18)):3287-3296 doi:10.1002/cncr.34355.

    PMID: 35819253
  14. 14

    Sequential Imaging of Suspicion of Prostate Cancer: Reducing Overdiagnosis and Unnecessary Biopsy with Timely Diagnosis of Significant Cancer (SPROUT)-Prospective Multicentre Cohort Study Protocol.

    Sweere V, de Rooij M, Kil PJM, et al.

    European urology oncology 2026; doi:10.1016/j.euo.2026.05.013.

    PMID: 42242939
  15. 15

    Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.

    Mazzone E, Stabile A, Pellegrino F, et al.

    European urology oncology 2021; (4(5)):697-713 doi:10.1016/j.euo.2020.12.004.

    PMID: 33358543
  16. 16

    Personalized prostate biopsy protocols: enhancing cancer detection through tailored approaches-a narrative review.

    Guo S, Jiang X

    Translational andrology and urology 2025; (14(3)):831-840 doi:10.21037/tau-24-619.

    PMID: 40226054
  17. 17

    Integrating Prostate-Specific Antigen Density and Prostate Imaging Reporting and Data System Scores to Optimize Detection of Clinically Significant Prostate Cancer: A Multivariable Risk Model Approach.

    Kayali Y

    Journal of clinical laboratory analysis 2026; (40(12)):e70218 doi:10.1002/jcla.70218.

    PMID: 41934174
  18. 18

    Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.

    Hofbauer SL, Maxeiner A, Kittner B, et al.

    The Journal of urology 2018; (200(4)):767-773 doi:10.1016/j.juro.2018.05.003.

    PMID: 29733838
  19. 19

    Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study.

    Elkhoury FF, Felker ER, Kwan L, et al.

    JAMA surgery 2019; (154(9)):811-818 doi:10.1001/jamasurg.2019.1734.

    PMID: 31188412
  20. 20

    Can we omit systematic biopsies in patients undergoing MRI fusion-targeted prostate biopsies?

    Leow JJ, Koh SH, Chow MW, et al.

    Asian journal of andrology 2023; (25(1)):43-49 doi:10.4103/aja2021128.

    PMID: 35488666
  21. 21

    Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.

    Ahdoot M, Lebastchi AH, Long L, et al.

    European urology oncology 2022; (5(2)):176-186 doi:10.1016/j.euo.2021.03.004.

    PMID: 33846112
  22. 22

    Assessment of prostate imaging reporting and data system version 2.1 false-positive category 4 and 5 lesions in clinically significant prostate cancer.

    Wang X, Liu W, Lei Y, et al.

    Abdominal radiology (New York) 2021; (46(7)):3410-3417 doi:10.1007/s00261-021-03023-w.

    PMID: 33710384
  23. 23

    Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice.

    Sokhi HK, Padhani AR, Patel S, Pope A

    Clinical radiology 2020; (75(12)):950-956 doi:10.1016/j.crad.2020.08.011.

    PMID: 32919755
  24. 24

    Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy.

    Kornienko K, Reuter M, Maxeiner A, et al.

    Scientific reports 2022; (12(1)):13603 doi:10.1038/s41598-022-17260-6.

    PMID: 35948575
  25. 25

    Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.

    Arcot R, Sekar S, Kotamarti S, et al.

    Abdominal radiology (New York) 2022; (47(8)):2917-2927 doi:10.1007/s00261-022-03562-w.

    PMID: 35674785

This page explains prostate MRI PI-RADS scores for informational purposes only and does not constitute medical advice or diagnose prostate cancer. Ask your urologist and radiologist to interpret your results and discuss whether biopsy or monitoring is appropriate.